Cargando…
Epidemiology and survival outcomes of HIV-associated cervical cancer in Nigeria
INTRODUCTION: Invasive cervical cancer (ICC) is an HIV-associated cancer that is preventable and precancerous stages including early ICC stages could be detected through screening offering opportunities for treatment and cure. The high incidence in women living with HIV and late presentation often a...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619301/ https://www.ncbi.nlm.nih.gov/pubmed/37915091 http://dx.doi.org/10.1186/s13027-023-00550-7 |
_version_ | 1785129958766542848 |
---|---|
author | Musa, Jonah Kocherginsky, Masha Magaji, Francis A. Maryam, Ali J. Asufi, Joyce Nenrot, Danjuma Burdett, Kirsten Katam, Neelima Christian, Elizabeth N. Palanisamy, Nisha Odukoya, Olukemi Silas, Olugbenga A. Abdulkareem, Fatimah Akpa, Philip Badmos, Kabir Imade, Godwin E. Akanmu, Alani S. Gursel, Demirkan B. Zheng, Yinan Joyce, Brian T. Achenbach, Chad J. Sagay, Atiene S. Anorlu, Rose Wei, Jian-Jun Ogunsola, Folasade Murphy, Robert L. Hou, Lifang Simon, Melissa A. |
author_facet | Musa, Jonah Kocherginsky, Masha Magaji, Francis A. Maryam, Ali J. Asufi, Joyce Nenrot, Danjuma Burdett, Kirsten Katam, Neelima Christian, Elizabeth N. Palanisamy, Nisha Odukoya, Olukemi Silas, Olugbenga A. Abdulkareem, Fatimah Akpa, Philip Badmos, Kabir Imade, Godwin E. Akanmu, Alani S. Gursel, Demirkan B. Zheng, Yinan Joyce, Brian T. Achenbach, Chad J. Sagay, Atiene S. Anorlu, Rose Wei, Jian-Jun Ogunsola, Folasade Murphy, Robert L. Hou, Lifang Simon, Melissa A. |
author_sort | Musa, Jonah |
collection | PubMed |
description | INTRODUCTION: Invasive cervical cancer (ICC) is an HIV-associated cancer that is preventable and precancerous stages including early ICC stages could be detected through screening offering opportunities for treatment and cure. The high incidence in women living with HIV and late presentation often at advanced stages of ICC with limited treatment facilities often result in early mortality. We sought to compare the epidemiologic characteristics and survival differences in HIV status of ICC patients in Nigeria. METHODS: We conducted a cohort study at two federal academic hospital-based research sites in Jos University Teaching Hospital, and Lagos University Teaching Hospital Nigeria, between March 2018 and September 2022. We enrolled women with histologically confirmed ICC with known HIV status, and FIGO staging as part of the United States of America’s National Institutes of Health/National Cancer Institute funded project titled ‘Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria’. The primary outcome was all-cause mortality with assessment of overall survival (OS) and time to death after ICC diagnosis. OS distribution was estimated using the method of Kaplan–Meier and compared between groups using the log-rank test. RESULTS: A total of 239 women with confirmed ICC were enrolled and included in this analysis, of whom 192 (80.3%) were HIV-negative (HIV−/ICC +), and 47 (19.7%) were HIV-positive (HIV +/ICC +). The HIV +/ICC + patients were younger with median age 46 (IQR: 40–51) years compared to 57 (IQR: 45–66) among HIV−/ICC + (P < 0.001). Squamous cell carcinoma was the commonest histopathologic variant in 80.4% of ICC diagnosis, moderately differentiated tumor grade in 68.1% in both groups. HIV +/ICC + diagnosis was at FIGO advanced stages in 64.9% compared to 47.9% in HIV−/ICC +. The HIV−/ICC + women had better OS compared to HIV +/ICC + participants (p = 0.018), with 12-month OS 84.1% (95%CI 75–90%) and 67.6% (95%CI 42–84%) respectively. CONCLUSION: ICC is diagnosed at a relatively young age in women living with HIV, with a significantly lower overall survival probability compared to women without HIV. The trend of presentation and diagnosis at advanced stages in women living with HIV could partly explain the differences in overall survival. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13027-023-00550-7. |
format | Online Article Text |
id | pubmed-10619301 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106193012023-11-02 Epidemiology and survival outcomes of HIV-associated cervical cancer in Nigeria Musa, Jonah Kocherginsky, Masha Magaji, Francis A. Maryam, Ali J. Asufi, Joyce Nenrot, Danjuma Burdett, Kirsten Katam, Neelima Christian, Elizabeth N. Palanisamy, Nisha Odukoya, Olukemi Silas, Olugbenga A. Abdulkareem, Fatimah Akpa, Philip Badmos, Kabir Imade, Godwin E. Akanmu, Alani S. Gursel, Demirkan B. Zheng, Yinan Joyce, Brian T. Achenbach, Chad J. Sagay, Atiene S. Anorlu, Rose Wei, Jian-Jun Ogunsola, Folasade Murphy, Robert L. Hou, Lifang Simon, Melissa A. Infect Agent Cancer Research INTRODUCTION: Invasive cervical cancer (ICC) is an HIV-associated cancer that is preventable and precancerous stages including early ICC stages could be detected through screening offering opportunities for treatment and cure. The high incidence in women living with HIV and late presentation often at advanced stages of ICC with limited treatment facilities often result in early mortality. We sought to compare the epidemiologic characteristics and survival differences in HIV status of ICC patients in Nigeria. METHODS: We conducted a cohort study at two federal academic hospital-based research sites in Jos University Teaching Hospital, and Lagos University Teaching Hospital Nigeria, between March 2018 and September 2022. We enrolled women with histologically confirmed ICC with known HIV status, and FIGO staging as part of the United States of America’s National Institutes of Health/National Cancer Institute funded project titled ‘Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria’. The primary outcome was all-cause mortality with assessment of overall survival (OS) and time to death after ICC diagnosis. OS distribution was estimated using the method of Kaplan–Meier and compared between groups using the log-rank test. RESULTS: A total of 239 women with confirmed ICC were enrolled and included in this analysis, of whom 192 (80.3%) were HIV-negative (HIV−/ICC +), and 47 (19.7%) were HIV-positive (HIV +/ICC +). The HIV +/ICC + patients were younger with median age 46 (IQR: 40–51) years compared to 57 (IQR: 45–66) among HIV−/ICC + (P < 0.001). Squamous cell carcinoma was the commonest histopathologic variant in 80.4% of ICC diagnosis, moderately differentiated tumor grade in 68.1% in both groups. HIV +/ICC + diagnosis was at FIGO advanced stages in 64.9% compared to 47.9% in HIV−/ICC +. The HIV−/ICC + women had better OS compared to HIV +/ICC + participants (p = 0.018), with 12-month OS 84.1% (95%CI 75–90%) and 67.6% (95%CI 42–84%) respectively. CONCLUSION: ICC is diagnosed at a relatively young age in women living with HIV, with a significantly lower overall survival probability compared to women without HIV. The trend of presentation and diagnosis at advanced stages in women living with HIV could partly explain the differences in overall survival. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13027-023-00550-7. BioMed Central 2023-11-01 /pmc/articles/PMC10619301/ /pubmed/37915091 http://dx.doi.org/10.1186/s13027-023-00550-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Musa, Jonah Kocherginsky, Masha Magaji, Francis A. Maryam, Ali J. Asufi, Joyce Nenrot, Danjuma Burdett, Kirsten Katam, Neelima Christian, Elizabeth N. Palanisamy, Nisha Odukoya, Olukemi Silas, Olugbenga A. Abdulkareem, Fatimah Akpa, Philip Badmos, Kabir Imade, Godwin E. Akanmu, Alani S. Gursel, Demirkan B. Zheng, Yinan Joyce, Brian T. Achenbach, Chad J. Sagay, Atiene S. Anorlu, Rose Wei, Jian-Jun Ogunsola, Folasade Murphy, Robert L. Hou, Lifang Simon, Melissa A. Epidemiology and survival outcomes of HIV-associated cervical cancer in Nigeria |
title | Epidemiology and survival outcomes of HIV-associated cervical cancer in Nigeria |
title_full | Epidemiology and survival outcomes of HIV-associated cervical cancer in Nigeria |
title_fullStr | Epidemiology and survival outcomes of HIV-associated cervical cancer in Nigeria |
title_full_unstemmed | Epidemiology and survival outcomes of HIV-associated cervical cancer in Nigeria |
title_short | Epidemiology and survival outcomes of HIV-associated cervical cancer in Nigeria |
title_sort | epidemiology and survival outcomes of hiv-associated cervical cancer in nigeria |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619301/ https://www.ncbi.nlm.nih.gov/pubmed/37915091 http://dx.doi.org/10.1186/s13027-023-00550-7 |
work_keys_str_mv | AT musajonah epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT kocherginskymasha epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT magajifrancisa epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT maryamalij epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT asufijoyce epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT nenrotdanjuma epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT burdettkirsten epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT katamneelima epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT christianelizabethn epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT palanisamynisha epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT odukoyaolukemi epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT silasolugbengaa epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT abdulkareemfatimah epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT akpaphilip epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT badmoskabir epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT imadegodwine epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT akanmualanis epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT gurseldemirkanb epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT zhengyinan epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT joycebriant epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT achenbachchadj epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT sagayatienes epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT anorlurose epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT weijianjun epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT ogunsolafolasade epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT murphyrobertl epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT houlifang epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT simonmelissaa epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria |